4//SEC Filing
CORIXA CORP 4
Accession 0001181340-05-000001
CIK 0001042561operating
Filed
Jul 13, 8:00 PM ET
Accepted
Jul 14, 5:02 PM ET
Size
22.7 KB
Accession
0001181340-05-000001
Insider Transaction Report
Form 4
CORIXA CORPCRXA
MOMSEN ROBERT R
Director
Transactions
- Disposition to Issuer
Common Stock
2005-07-12$4.40/sh−501,500$2,206,600→ 0 total(indirect: by InterWest Partners V, LP) - Disposition to Issuer
Common Stock
2005-07-12$4.40/sh−3,154$13,878→ 0 total(indirect: by InterWest Investors V, LP) - Disposition to Issuer
NQ Option (Right to Buy)
2005-07-12−20,060→ 0 totalExercise: $8.60From: 2003-07-30Exp: 2007-07-29→ Common Stock (20,060 underlying) - Disposition to Issuer
Common Stock
2005-07-12$4.40/sh−81,174$357,166→ 0 total - Disposition to Issuer
NQ Option (Right to Buy)
2005-07-12−15,000→ 0 totalExercise: $25.13From: 2005-07-12Exp: 2010-12-22→ Common Stock (15,000 underlying) - Disposition to Issuer
NQ Option (Right to Buy)
2005-07-12−5,000→ 0 totalExercise: $5.07From: 2005-07-12Exp: 2014-05-28→ Common Stock (5,000 underlying) - Disposition to Issuer
NQ Option (Right to Buy)
2005-07-12−7,500→ 0 totalExercise: $5.07From: 2005-07-12Exp: 2014-05-28→ Common Stock (7,500 underlying)
Footnotes (6)
- [F1]Disposed of pursuant to a merger agreement between the Issuer and GlaxoSmithKline PLC
- [F2]The shares are held by InterWest Partners V, LP ("IW5"). The general partner of IW5 is InterWest Management Partners V, LP ("IMP5"). The Reporting Person is a General Partner of IMP5 and disclaims beneficial ownership of the shares held by IW5 except to the extent of his pecuniary interest therein.
- [F3]The shares are held by InterWest Investors V ("II5"). The Reporting Person is a General Partner of II5 and disclaims beneficial ownership of the shares held by II5 except to the extent of his pecuniary interest therein.
- [F4]Option vests in 36 equal monthly installments and was fully vested prior to 7/12/05. The option was cancelled pursuant to the merger agreement between the Issuer and GlaxoSmithKline PLC. No cash consideration was received.
- [F5]Option vests in 12 equal monthly installments and was fully vested prior to 7/12/05. The option was cancelled pursuant to the merger agreement between the Issuer and GlaxoSmithKline PLC. No cash consideration was received.
- [F6]Option was fully vested prior to 7/12/05. The option was cancelled pursuant to the merger agreement between the Issuer and GlaxoSmithKline PLC. No cash consideration was received.
Documents
Issuer
CORIXA CORP
CIK 0001042561
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001042561
Filing Metadata
- Form type
- 4
- Filed
- Jul 13, 8:00 PM ET
- Accepted
- Jul 14, 5:02 PM ET
- Size
- 22.7 KB